Lantern Pharma Inc. LTRN
Biotechnology: Pharmaceutical Preparations · IPO 2020 · data as of November 13, 2026
Lantern Pharma Inc. (LTRN) is a healthcare company listed in the US with a market value of about $6M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -73%.
About Lantern Pharma
Lantern Pharma is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2020. It was profitable in 0 of the last 7 years in our data.
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — |
| Net income | -$17M | -$21M | -$16M | -$14M | -$12M | -$6M | -$2M |
| Free cash flow | -$16M | -$18M | -$14M | -$13M | -$11M | — | — |
| EPS (diluted) | $-1.57 | $-1.93 | $-1.47 | $-1.31 | $-1.13 | $-1.37 | $-1.23 |
| Net margin | — | — | — | — | — | — | — |
| ROIC | -214.8% | -81.9% | -34.3% | -20.3% | -13.9% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Lantern Pharma pay a dividend?
Not currently.
Is Lantern Pharma a good stock to buy?
We do not give buy or sell advice. Lantern Pharma scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.